Loading organizations...
Based in Lausanne, Switzerland, Alithea Genomics develops proprietary Bulk RNA Barcoding and sequencing technologies to facilitate highly scalable transcriptomics for biomarker discovery, high-throughput drug screening, and biobanking. The company commercializes its proprietary MERCURIUS library preparation kits alongside comprehensive end-to-end sequencing and bioinformatics data analysis services for pharmaceutical companies, biotechnology firms, and academic research institutions. Operating with an estimated 21 to 50 employees, the growing enterprise generates approximately $2,652,000 in estimated annual revenue and holds an estimated valuation of $8,500,000. To support its recent commercial expansion into the US market, the firm has raised over $3,742,000 in total funding from prominent investors including Novalis Biotech, TechU Ventures, and High-Tech Gründerfonds. Originally established as a spin-off from the Swiss Federal Institute of Technology Lausanne, the enterprise was founded in 2020 by Riccardo Dainese, Daniel Alpern, and Bart Deplancke.
Alithea Genomics has raised $13.8M across 7 funding rounds.
Alithea Genomics has raised $13.8M in total across 7 funding rounds.
Alithea Genomics has raised $13.8M across 7 funding rounds. Most recently, it raised $8.8M Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 4, 2026 | $8.8M Seed | Genku Ventures | JAN VAN DEN Berghe, Zürcher Kantonalbank | Announced |
| Mar 1, 2024 | $3M Seed | JAN VAN DEN Berghe | 305 Ventures, FF Venture Capital, Mayfield, SOSV, Starbridge Venture Capital, Techu Angels, Ning Sung | Announced |
| Mar 21, 2023 | $540K Debt Financing | Foundation For Technological Innovation | — | Announced |
| May 24, 2022 | $1M Seed | JAN VAN DEN Berghe | — | Announced |
| Apr 28, 2021 | $160K Grant | Jordi Montserrat | — | Announced |
| Mar 11, 2021 | $110K Debt Financing | FIT | — | Announced |
| Jul 31, 2020 | $110K Grant | EPFL, FIT | — | Announced |
Alithea Genomics has raised $13.8M in total across 7 funding rounds.
Alithea Genomics's investors include Genku Ventures, Jan Van den Berghe, Zürcher Kantonalbank, 305 Ventures, ff Venture Capital, Mayfield, SOSV, Starbridge Venture Capital, TechU Angels, Ning Sung, Foundation for Technological Innovation, Jordi Montserrat.
Alithea Genomics is a technology company specializing in scalable, cost-efficient transcriptomics solutions that enable large-scale RNA sequencing for drug screening, biomarker discovery, and biomedical research. Their proprietary technologies, including Mercurius™ DRUG-seq and BRB-seq, optimize operational costs and significantly increase sample throughput by enabling massive multiplexing and eliminating RNA extraction steps. They serve pharmaceutical companies, biotech firms, research institutions, and agrochemical clients, helping them accelerate and de-risk compound selection and fundamental research through high-throughput gene expression profiling[1][2][3].
Founded in 2020 in Epalinges, Switzerland, Alithea Genomics was established by Bart Deplancke, Daniel Alpern, and Riccardo Dainese. The founders brought expertise in genomics and bioinformatics to address the high costs and technical limitations of traditional RNA sequencing methods. The idea emerged from the need to streamline transcriptomics workflows, enabling researchers to process thousands of samples efficiently and cost-effectively. Early traction came from validating their RNA extraction-free protocols on diverse sample types such as frozen cells, organoids, and FFPE tissues, which helped position them as a leader in scalable transcriptomics for screening applications[1][4][6].
Alithea Genomics rides the growing trend of high-throughput, cost-effective transcriptomics that is transforming drug discovery and biomedical research. The timing is critical as pharmaceutical and biotech industries increasingly rely on large-scale gene expression data to accelerate compound screening and biomarker identification. Market forces such as the demand for precision medicine, multi-omics integration, and scalable screening platforms favor Alithea’s solutions. By lowering barriers to large-scale RNA sequencing, Alithea influences the broader ecosystem by enabling faster, more data-rich decision-making in drug development and agricultural biotech[3][5].
Looking ahead, Alithea Genomics is poised to expand its impact by further scaling its technologies and broadening applications in pharma, biotech, and agrochemical sectors. Trends such as multi-omics integration, AI-driven data analysis, and personalized medicine will shape their journey, potentially driving adoption of their high-throughput transcriptomics platforms. Their influence may evolve from a technology provider to a key enabler of next-generation drug discovery and biomarker research, helping to unlock new biological insights at unprecedented scale and speed[5].
In summary, Alithea Genomics stands out by delivering scalable, cost-effective RNA sequencing solutions that address critical bottlenecks in biomedical research, positioning them as a transformative player in the genomics technology landscape.
